Global Leading Market Research Publisher QYResearch announces the release of its latest report “Biological Intelligent Pump – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Biological Intelligent Pump market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Biological Intelligent Pump was estimated to be worth US$ 252 million in 2025 and is projected to reach US$ 364 million, growing at a CAGR of 5.5% from 2026 to 2032.
The bio-intelligent pump is an intelligent fluid control device designed specifically for biological experiments and biopharmaceutical processes. It precisely regulates flow rate, pressure, and volume, and integrates sensors, a microprocessor, and a communication module. It monitors fluid delivery status (such as blockages, bubbles, and leaks) in real time, supporting automatic feedback regulation, programmed operation, and remote monitoring. Widely used in liquid chromatography, cell culture, perfusion systems, bioreactors, and microfluidic chips, the pump is compatible with sensitive biological samples (such as proteins, cells, and exosomes), ensuring low-shear, low-contamination, and highly stable fluid delivery. It is a key component for achieving automated and intelligent bioprocesses.In 2024, the global production of bio-intelligent pumps will reach 86,170 units, with an average selling price of US,797 per unit.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6099000/biological-intelligent-pump
1. Industry Pain Points and the Shift Toward Intelligent Bioprocess Fluid Control
Biopharmaceutical manufacturing and life science research require precise, gentle fluid handling for sensitive biological samples (cells, proteins, exosomes). Traditional peristaltic and diaphragm pumps lack real-time monitoring, automated feedback, and data logging capabilities, leading to inconsistent flow, sample damage, and process deviations. Biological intelligent pumps address this by integrating sensors (pressure, flow, bubble detection), microprocessors, and communication modules for real-time monitoring and automatic feedback regulation. For bioprocess engineers and researchers, these pumps provide low-shear fluid delivery, programmable operation, and remote control, ensuring reproducible results and regulatory compliance in applications such as cell culture, perfusion systems, bioreactors, and liquid chromatography.
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global biological intelligent pump market was valued at US$ 252 million in 2025 and is projected to reach US$ 364 million by 2032, growing at a CAGR of 5.5%. In 2024, global production reached approximately 86,170 units with an average selling price of US$ 2,797 per unit. Market growth is driven by three factors: expansion of biopharmaceutical R&D and manufacturing (mAbs, cell therapies, gene therapies), increasing adoption of automated bioprocessing (Industry 4.0 in pharma), and demand for data integrity and regulatory compliance (FDA 21 CFR Part 11, GAMP).
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four notable developments:
- Cell therapy manufacturing growth: CAR-T and stem cell therapy production requires precise, low-shear fluid handling for cell viability. Cell therapy segment grew 18% year-over-year.
- Single-use bioprocessing integration: Intelligent pumps with single-use flow paths (Watson-Marlow, Levitronix) gained 25% market share, reducing cross-contamination risk and cleaning validation burden.
- Remote monitoring adoption: Cloud-connected intelligent pumps (Smart-Pumps.eu, GL Sciences) enable remote operation and data access for distributed bioprocessing. IoT-enabled segment grew 30% in 2025.
- Chinese supplier expansion: H&E Co., Ltd, Rongjie Biotechnology (Suzhou) Co., Ltd., Holves, and others increased production by 35% collectively, capturing share in domestic biopharma market.
4. Competitive Landscape and Key Suppliers
The market includes global bioprocessing equipment leaders and Chinese specialists:
- H&E Co., Ltd (China), Rongjie Biotechnology (Suzhou) Co., Ltd. (China), Holves (China), Watson-Marlow (UK – peristaltic pump leader), Smart-Pumps.eu (Netherlands), GL Sciences (Japan), INNOVA Biomed (Spain), CP Pumpen AG (Switzerland), Levitronix (Switzerland – magnetic levitation pumps), Supermag (China).
Competition centers on three axes: flow accuracy (±%), shear sensitivity (low-shear design), and automation level (programmable, remote monitoring).
5. Segment-by-Segment Analysis: Type and Application
By Pump Type
- Peristaltic Pump: Most common for biological applications. Fluid contained in disposable tubing, no contact with pump components. Low shear, easy sterilization, single-use compatible. Account for ~70% of market. Watson-Marlow, H&E, Rongjie, Holves, Supermag lead.
- Diaphragm Pump: Higher pressure capability, lower pulsation. Used in chromatography and filtration. Account for ~30% of market. Levitronix (maglev diaphragm), CP Pumpen, INNOVA Biomed, Smart-Pumps.eu lead.
By Application
- Biomedicine: Largest segment (~60% of market). Biopharmaceutical manufacturing (mAbs, vaccines), cell therapy production, perfusion systems, bioreactor feeding, chromatography.
- Scientific Research: (~30% of market). Academic labs, research institutes, drug discovery. Microfluidic chips, cell culture, protein purification.
- Other: Diagnostic equipment, clinical analyzers, food testing. ~10% of market.
User case – Cell therapy manufacturing: A cell therapy company (CAR-T) deployed 50 intelligent peristaltic pumps (Watson-Marlow, single-use flow paths) in their GMP manufacturing suite. Pumps maintain low shear (cell viability >95%) and provide real-time flow, pressure, and bubble detection. Automated data logging (21 CFR Part 11) eliminated manual record-keeping errors. Pump accuracy: ±1% flow rate, ±2% pressure. Annual audit findings related to fluid handling reduced by 80%.
6. Exclusive Insight: Manufacturing – Intelligent Pump Control and Monitoring
Intelligent biological pumps integrate multiple sensors and control features:
Key Features:
| Feature | Description | Benefit |
|---|---|---|
| Flow control | Closed-loop PID control | ±0.5-1% accuracy |
| Pressure monitoring | Inline pressure sensor | Occlusion detection, pressure limit alarms |
| Bubble detection | Ultrasonic or optical sensor | Air-in-line prevention (critical for perfusion) |
| Leak detection | Capacitive or optical sensor | Prevents contamination and sample loss |
| Data logging | On-board memory or cloud | Traceability, compliance |
| Programmable operation | Schedules, ramps, multi-step protocols | Automation, reproducibility |
| Remote monitoring | Ethernet, Wi-Fi, 4G | Off-site operation, alarm notification |
Low-Shear Design Considerations:
- Peristaltic: Large diameter tubing, slow roller speed, soft roller material
- Diaphragm: Gentle diaphragm motion, no sharp edges, smooth flow path
- Maglev (Levitronix) : Contactless impeller suspension, zero mechanical friction
Technical challenge: Maintaining low shear while achieving accurate flow control. High shear damages cells (ruptures membranes), reduces viability, and affects product quality. Premium intelligent pumps (Watson-Marlow, Levitronix) use:
- Flow-optimized flow paths (smooth transitions, no sharp corners)
- Shear-minimizing pump heads (large tube diameter, soft rollers)
- Flow profiles (ramped start/stop, smooth acceleration)
User case – Shear sensitivity comparison: A cell culture study compared cell viability after pumping through different pump types (100 mL/min, 30 minutes). Peristaltic (Watson-Marlow, large tube): 98% viability. Standard diaphragm pump: 85% viability (shear damage). Levitronix maglev: 97% viability. Peristaltic recommended for shear-sensitive cells (stem cells, primary cells).
7. Regional Outlook and Strategic Recommendations
- North America: Largest market (35% share, CAGR 5%). US (biopharma hub), Canada. Watson-Marlow, Levitronix, Smart-Pumps.eu strong.
- Europe: Second-largest (30% share, CAGR 5%). UK (Watson-Marlow), Switzerland (CP Pumpen, Levitronix), Netherlands (Smart-Pumps.eu), Spain (INNOVA Biomed). Strong biopharma and research base.
- Asia-Pacific: Fastest-growing region (CAGR 6.5%). China (H&E, Rongjie, Holves, Supermag), Japan (GL Sciences), South Korea. Biopharma capacity expansion driving demand.
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The biological intelligent pump market is positioned for steady growth through 2032, driven by biopharmaceutical expansion, cell therapy manufacturing, and automation demands. Stakeholders—from pump manufacturers to bioprocess engineers—should prioritize low-shear designs (peristaltic for cell culture), real-time monitoring (pressure, bubble, leak detection), and data logging for regulatory compliance. By enabling low-shear fluid delivery and real-time monitoring, biological intelligent pumps are essential for automated, compliant bioprocessing.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
